Login to Your Account



Spinifex seeks funding to advance neuropathic pain drug to phase IIb

By Nuala Moran
Staff Writer

Tuesday, February 4, 2014
LONDON – Spinifex Pharmaceuticals announced the publication of positive Phase IIa data for EMA401, a first-in-class oral treatment for chronic neuropathic pain, and said it is now in the process of raising $40 million to $50 million to fund a broad Phase IIb program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription